Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

JAK2 mutation-negative essential thrombocythemia in a child presenting with cerebral venous thrombosis.

Khan AA, Kumar V, Anand I, Kumar M, Sharma P, Bhargava M.

Hematol Oncol Stem Cell Ther. 2012;5(1):66-8. doi: 10.5144/1658-3876.2012.66.

2.

JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.

Allegra A, Alonci A, Penna G, D'Angelo A, Rizzotti P, Granata A, Musolino C.

Acta Haematol. 2009;121(4):218-20. doi: 10.1159/000221962. Epub 2009 May 29.

PMID:
19478480
3.

Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.

De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Cacciola E, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Leone G, Barbui T; GIMEMA Chronic Myeloproliferative Neoplasms Working Party..

Ann Hematol. 2010 Feb;89(2):141-6. doi: 10.1007/s00277-009-0788-5. Epub 2009 Jul 7.

PMID:
19582452
4.

JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis.

Kurosawa H, Okuya M, Matsushita T, Kubota T, Endoh K, Kuwashima S, Hagisawa S, Sato Y, Fukushima K, Sugita K, Okada Y, Park MJ, Hayashi Y, Arisaka O.

J Pediatr Hematol Oncol. 2009 Sep;31(9):678-80. doi: 10.1097/MPH.0b013e3181b1ec9e.

PMID:
19707158
5.

Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.

Yoo EH, Jang JH, Park KJ, Gwak GY, Kim HJ, Kim SH, Kim DK.

Int J Lab Hematol. 2011 Oct;33(5):471-6. doi: 10.1111/j.1751-553X.2011.01308.x. Epub 2011 Mar 24.

PMID:
21435189
6.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
7.

Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies.

Veselovska J, Pospisilova D, Pekova S, Horvathova M, Solna R, Cmejlova J, Cmejla R, Belickova M, Mihal V, Stary J, Divoky V.

Leuk Res. 2008 Mar;32(3):369-77. Epub 2007 Aug 23.

PMID:
17719087
8.
9.

Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.

Nakatani T, Imamura T, Ishida H, Wakaizumi K, Yamamoto T, Otabe O, Ishigami T, Adachi S, Morimoto A.

Pediatr Blood Cancer. 2008 Dec;51(6):802-5. doi: 10.1002/pbc.21730.

PMID:
18802948
10.

Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia.

De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, Chiusolo P, Sica S, Leone G.

Haematologica. 2009 May;94(5):733-7. doi: 10.3324/haematol.13869. Epub 2009 Mar 31.

11.

[Cerebral venous thrombosis secondary to essential thrombocythemia].

Messouak O, Alaoui Faris M, Benabdejlil M, Tizniti S, Belahsen F.

Rev Neurol (Paris). 2007 May;163(5):596-8. French.

PMID:
17571029
12.

Essential thrombocythemia.

Brière JB.

Orphanet J Rare Dis. 2007 Jan 8;2:3. Review.

13.

Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.

PMID:
17369568
14.

[Vascular complications of essential thrombocythemia].

Bellucci S.

Bull Acad Natl Med. 2007 Mar;191(3):519-30; discussion 530-3. Review. French.

PMID:
18072651
15.

JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.

Michiels JJ, Commandeur S, Hoogenboom GJ, Wegman JJ, Scholten L, van Rijssel RH, De Raeve H.

Ann Hematol. 2007 Nov;86(11):793-800. Epub 2007 Aug 9. Review.

PMID:
17687555
16.

JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders.

Owens CD.

J Vasc Surg. 2010 Jul;52(1):205-7. doi: 10.1016/j.jvs.2010.01.097.

17.

Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.

Vannucchi AM.

Intern Emerg Med. 2010 Jun;5(3):177-84. doi: 10.1007/s11739-009-0319-3. Epub 2009 Sep 30. Review.

PMID:
19789961
18.

Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.

Weston H, Cowell V, Grimmett K, Saal R, Jones M, Mills T, Gill D, Marlton P, Bird R, Mollee P.

Intern Med J. 2011 May;41(5):408-15. doi: 10.1111/j.1445-5994.2010.02334.x. Epub 2010 Jul 30.

PMID:
20681956
19.

Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.

Dua V, Yadav SP, Kumar V, Saxena R, Sachdeva A.

Int J Hematol. 2012 Dec;96(6):810-3. doi: 10.1007/s12185-012-1193-8. Epub 2012 Oct 7.

PMID:
23054653
20.

The JAK2 V617F mutation in patients with cerebral venous thrombosis.

Passamonti SM, Biguzzi E, Cazzola M, Franchi F, Gianniello F, Bucciarelli P, Pietra D, Mannucci PM, Martinelli I.

J Thromb Haemost. 2012 Jun;10(6):998-1003. doi: 10.1111/j.1538-7836.2012.04719.x.

Supplemental Content

Support Center